KIRLYNXA Trademark

Trademark Overview

On Thursday, August 13, 2020, a trademark application was filed for KIRLYNXA with the United States Patent and Trademark Office. The USPTO has given the KIRLYNXA trademark a serial number of 90112426. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 13, 2023. This trademark is owned by AbbVie Inc.. The KIRLYNXA trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders
kirlynxa

General Information

Serial Number90112426
Word MarkKIRLYNXA
Filing DateThursday, August 13, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 13, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 17, 2020

Trademark Statements

Goods and Servicespharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, September 17, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAbbVie Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNorth Chicago, IL 60064
Party NameAbbVie Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNorth Chicago, IL 60064

Trademark Events

Event DateEvent Description
Monday, February 13, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 13, 2023ABANDONMENT - NO USE STATEMENT FILED
Saturday, July 2, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 30, 2022SOU EXTENSION 3 GRANTED
Thursday, June 30, 2022SOU EXTENSION 3 FILED
Thursday, June 30, 2022TEAS EXTENSION RECEIVED
Friday, December 24, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 22, 2021SOU EXTENSION 2 GRANTED
Wednesday, December 22, 2021SOU EXTENSION 2 FILED
Wednesday, December 22, 2021TEAS EXTENSION RECEIVED
Saturday, July 10, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 8, 2021SOU EXTENSION 1 GRANTED
Thursday, July 8, 2021SOU EXTENSION 1 FILED
Thursday, July 8, 2021TEAS EXTENSION RECEIVED
Tuesday, January 12, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 17, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 17, 2020PUBLISHED FOR OPPOSITION
Wednesday, October 28, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 13, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, September 22, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, September 21, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, September 21, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, September 18, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, September 18, 2020NON-FINAL ACTION E-MAILED
Friday, September 18, 2020NON-FINAL ACTION WRITTEN
Friday, September 18, 2020ASSIGNED TO EXAMINER
Thursday, September 17, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, August 17, 2020NEW APPLICATION ENTERED

Related Keywords

kirlynxa gastrointestinal hormonal neurological respiratory ophthalmic dermatological psychiatric diseases disorders related